Journal of Research in Medical Sciences最新文献

{"title":"The frequency of NRAS mutation in stool samples of Iranian colorectal cancers compared to Finnish patients.","authors":"Farideh Saberi, Omar Youssef, Arto Kokkola, Mahsa Khodadoostan, Pauli Puolakkainen, Rasoul Salehi, Sakari Knuutila","doi":"10.4103/jrms.jrms_208_23","DOIUrl":"10.4103/jrms.jrms_208_23","url":null,"abstract":"<p><strong>Background: </strong>Stools from colorectal cancer patients are noninvasive samples that could be used to compare the frequency of hotspot mutations between two different ethnic cohorts.</p><p><strong>Materials and methods: </strong>We collected stool samples from the Iranian cohort (52 patients and 49 controls) and the Finnish cohort (40 patients and 14 controls). Following stool DNA extraction, we used the AmpliSeq Colon and Lung Cancer panel to prepare DNA libraries before sequencing.</p><p><strong>Results: </strong>The Iranian cohort exhibited 35 hotspot mutations in the <i>BRAF</i>, <i>ERBB4</i>, <i>FBXW7</i>, <i>FGFR1</i>, <i>FGFR3</i>, <i>KRAS</i>, <i>MAP2K</i>, <i>MET</i>, <i>NRAS</i>, <i>PIK3C</i>, <i>SMAD4</i>, and <i>TP53</i> genes. In the Finnish cohort, 13 hotspot mutations were found in the <i>AKT1</i>, <i>APC</i>, <i>KIT</i>, <i>KRAS</i>, <i>SMO</i>, <i>STK11</i>, and <i>TP53</i> genes. Mutations in <i>NRAS</i> and <i>FGFR3</i> were observed only in the Iranian cohort, while <i>APC</i> mutations were exclusive for the Finnish cohort.</p><p><strong>Conclusion: </strong>Genes involved in MAPK and PI3K-MAPK pathways showed a higher frequency of mutations in Iranian patients which may have therapeutic implications.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"4"},"PeriodicalIF":1.6,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10956560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does metabolic syndrome increase contrast-induced nephropathy in patients with normal renal function?","authors":"Hasan Shemirani, Ali Hosseini","doi":"10.4103/jrms.jrms_136_21","DOIUrl":"10.4103/jrms.jrms_136_21","url":null,"abstract":"<p><strong>Background: </strong>Contrast-induced nephropathy (CIN) is associated with increased mortality and morbidity in patients undergoing coronary angiography (CAG) and percutaneous coronary intervention. This study aimed to compare the incidence of CIN in two groups of patients with and without metabolic syndrome (Mets) with baseline normal renal function.</p><p><strong>Materials and methods: </strong>In this case - control study, 260 patient candidates for CAG, 130 patients with Mets and 130 patients without Mets participated, and their serum creatinine (Cr) level before and the 48 and 72 h after the angiography was measured. The incidence of CIN was compared in two groups. Two-way analysis of variance with repeated measures and univariate and multivariate logistic regression models.</p><p><strong>Results: </strong>The results showed a higher chance of being Mets with raising in triglyceride (adjusted odds ratio = 1.05, 95% confidence interval = (1.03-1.06), <i>P</i> < 0.001), Fasting blood glucose (1.010 [1.001-1.019], <i>P</i> = 0.025), and diastolic blood pressure (1.07 [1.07-1.20], <i>P</i> < 0.001), but declining in high-density lipoprotein-cholesterol (HDL-C) (0.91 [0.85-0.98], <i>P</i> = 0.008). Furthermore, blood urea nitrogen (BUN) and Cr level was raised in 48 and 72 h after contrast injection in both groups (All <i>P</i> < 0.001). Furthermore, in 48 h (3.11 [1.12-9.93], <i>P</i> = 0.016) and 72 h (2.82 [1.07-8.28], <i>P</i> = 0.021) after injection, a total of 25 patients had an increased Cr level and a significant difference between Mets and without Mets groups. The developing Mets had a significant association with the increased risk of AKI, which increased the chance of developing nephropathy (7.14 [2.27-22.5], <i>P</i> = 0.001).</p><p><strong>Conclusion: </strong>Mets, together with other risk factors, increased the overall risk of CIN development. Therefore, the incidence of CIN in patients Mets is significantly higher than that of patients without Mets, indicating a more important CIN risk factor.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"5"},"PeriodicalIF":1.6,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10956558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Metformin: Current knowledge.","authors":"","doi":"10.4103/JRMS.JRMS_62_24","DOIUrl":"10.4103/JRMS.JRMS_62_24","url":null,"abstract":"<p><p>[This corrects the article on p. 658 in vol. 19, PMID: 25364368.].</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"29 ","pages":"6"},"PeriodicalIF":1.6,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10956562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avascular necrosis predictive factors after closed reduction in patients with developmental dysplasia of the hip.","authors":"Sara Kheiri, Mohammad Ali Tahririan, Soheil Shahnaser, Mohammadreza Piri Ardakani","doi":"10.4103/jrms.jrms_288_23","DOIUrl":"10.4103/jrms.jrms_288_23","url":null,"abstract":"<p><strong>Background: </strong>Developmental dysplasia of the hip (DDH) is a common pediatric orthopedic condition. Closed reduction (CR) is the conservative treatment approach with high success rates for DDH. However, avascular necrosis (AVN) is a severe potential complication after this procedure. This study retrospectively assessed the potential risk factors for AVN occurrence after CR and Spica cast immobilization.</p><p><strong>Materials and methods: </strong>In a retrospective observational study, 71 patients (89 hips) with DDH aged 6-24 months old undergoing CR were enrolled. All patients were followed up for 3 years, and their demographic data, initial Tönnis grade, pre-reduction procedures, abduction angle in the Spica cast, and the AVN presence (based on Bucholz and Ogden classification [3^rd-4^th class]) were documented.</p><p><strong>Results: </strong>Of 71 patients (89 hips) with a mean age of 12.5 ± 3.9 months, 13 patients (18 hips) developed AVN. The mean age of patients in the AVN and non-AVN groups was 14.3 ± 4.9 and 12.2 ± 3 months (<i>P</i> = 0.07); also, the mean abduction angle in patients with and without AVN was 51.86 ± 3.66 and 58.46 ± 3.91 (<i>P</i> < 0.001) in univariate analysis. The distribution of initial Tönnis grade, and previous conservative procedures, adductor tenotomies during the CR were comparable between the two groups (<i>P</i> > 0.05). We found age 12 months and 54° in abduction angle as the best cutoff values for differentiating AVN patients from non-AVN and the risk of experiencing AVN for patients older than 12 months was odds ratio (OR) =4.22 (<i>P</i> = 0.06) and patients with abduction angle greater than 54 was OR = 34.88 (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>In this study, older age at the time of intervention and larger abduction angle in the hip Spica cast were two predictors of experiencing AVN in DDH patients after undergoing CR treatment approach. Performing CR at a younger age and keeping the abduction angle lower than 54° in the hip Spica cast could help to have the best possible prognosis.</p><p><strong>Level of evidence: </strong>IV, retrospective, observational, cross-sectional study.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"81"},"PeriodicalIF":1.5,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of serum lipid profile, fasting blood sugar, and body mass index on recurrence and metastasis in patients with estrogen receptor-positive breast cancer: A case-control study.","authors":"Iman Mohammadbeigy, Mohammad Sadegh Khalilian, Nadia Najafizadeh, Elham Moazam, Simin Hemati, Mehrdad Zeinalian","doi":"10.4103/jrms.jrms_163_22","DOIUrl":"10.4103/jrms.jrms_163_22","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is the leading cause of cancer death in women. The current study is designed to evaluate the association of lipid profiles, FBS, and body mass index (BMI) with BC recurrence and metastasis.</p><p><strong>Materials and methods: </strong>This is a case-control study on estrogen receptor-positive BC patients in Isfahan Province, Central Iran, between 2008 and 2020. The control group was patients who had no evidence of recurrence or metastasis at least 1 year after the end of chemotherapy and hormone therapy. The case group was patients with evidence of metastasis or recurrence within 1 year after the end of chemotherapy and hormone therapy. Fasting blood sugar (FBS), total cholesterol (Chol), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured before treatment, after chemotherapy, and after hormone therapy as well as BMI in the case and control groups.</p><p><strong>Results: </strong>There were 108 patients in the case and 119 patients in the control group with a mean age of 50.72 ± 13.26 and 51.91 ± 11.79, respectively. There were no meaningful differences between the case and control groups regarding serum FBS, Chol, TG, HDL, LDL, and BMI.</p><p><strong>Conclusion: </strong>We found no association between serum FBS, lipid profile, and BMI at initial diagnosis and BC recurrence or metastasis.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"83"},"PeriodicalIF":1.5,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of eptinezumab for migraine: A systematic review and meta-analysis.","authors":"Yi Zhong, Jiahe Wang, Hang Li, Siyuan Yang, Xiang Li, Heng Gao, Gang Chen","doi":"10.4103/jrms.jrms_306_22","DOIUrl":"10.4103/jrms.jrms_306_22","url":null,"abstract":"<p><strong>Background: </strong>Calcitonin gene-related peptides (CGRP) have been considered a new effective means to prevent and treat migraine. Eptinezumab is a new class of CGRP antagonists that has been ratified for clinical treatment. The purpose of this systematic review was to assess and contrast the therapeutic effect and safety of eptinezumab in the management of migraine in comparison with a placebo.</p><p><strong>Materials and methods: </strong>We systematically searched PubMed, Embase, Cochrane Library, and the US National Institutes of Health Clinical Trials Registry from the earliest date to February 16, 2023, for randomized controlled trials (RCTs). The mean difference (MD) and risk ratio (RR) were chosen to assess clinical indicators.</p><p><strong>Results: </strong>In total, there were 2, 739 patients in four RCTs, who were ultimately included. Our summarized results showed that eptinezumab had better healing efficacy compared to placebo with respect to monthly migraine days (MD = -1.56, 95% confidence interval [CI]: -2.32, -0.79, <i>P</i> < 0.001), improving ≥75% migraine responder rate (RR = 1.80, 95% CI: 1.40, 2.33, <i>P</i> < 0.001), ≥50% migraine responder rate (RR = 1.46, 95% CI: 1.33, 1.61, <i>P</i> < 0.001), and 100% migraine responder rate (RR = 2.41, 95% CI: 1.08, 5.38, <i>P</i> < 0.001). Furthermore, compared with placebo, there was no significant increase for treatment-related adverse events (RR = 1.01, 95% CI 0.94, 1.10, <i>P</i> = 0.71) and serious AEs (RR = 0.93, 95% CI 0.46, 1.90, <i>P</i> = 0.84). It was found that all dosages except for 10 mg had significant efficacy compared with placebo, especially 300 mg (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Eptinezumab has good healing efficacy and insignificant adverse effects in treating migraine, particularly the dosage of 300 mg.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"82"},"PeriodicalIF":1.5,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome evaluation of ECF, DCF, FOLFOX, and FLOT chemotherapy regimens as perioperative treatment in elderly patients with resectable gastric cancer; A retrospective comparative study.","authors":"Ali Forouhari, Azadeh Moghaddas, Ali Darakhshandeh","doi":"10.4103/jrms.jrms_417_22","DOIUrl":"10.4103/jrms.jrms_417_22","url":null,"abstract":"<p><strong>Background: </strong>The incidence of gastric cancer is known to be high in the elderly population. Identification of the best perioperative chemotherapy regimen is challenging in patients with resectable gastric cancer. In this study, we aimed to evaluate and compare the outcomes and safety of epirubicin, cisplatin, and 5-fluorouracil (ECF), docetaxel, cisplatin, and 5-fluorouracil (DCF), oxaliplatin plus 5-Fluorouracil and leucovorin (FOLFOX), and docetaxel, oxaliplatin, leucovorin, and 5-Fluorouracil (FLOT) chemotherapy regimens to identify the most appropriate treatment option for elderly patients with resectable gastric cancer.</p><p><strong>Materials and methods: </strong>In this retrospective observational cohort study, data were extracted from the medical archives (2017-2021) of Omid Hospital, which is a tertiary oncology referral hospital in Isfahan, Iran. Patients with resectable gastric cancer, above 60 years of age, who were perioperatively treated with one of the mentioned chemotherapy regimens and met the inclusion criteria, were enrolled in this study. The survival parameters and safety profile of the regimens were evaluated and compared in this population.</p><p><strong>Results: </strong>A total of 63 patients were included in this study. The median follow-up period of the patients was 24 months (range, 7-51 months). The results of survival analysis revealed that the FLOT and DCF regimens were significantly associated with longer overall survival (OS) as compared to the other regimens (median OS: 38 and 33 months, respectively). Based on the results, the progression-free survival was longer in the DCF regimen (median: 24 months) compared to the other regimens; however, only the difference with the ECF regimen (median: 14 months) was significant. The results of Cox regression analysis showed no significant difference in the overall adjusted hazard ratio of mortality between the FLOT and DCF regimens (<i>P</i> = 0.802). The DCF and FOLFOX regimens accounted for the highest and lowest rates of adverse events (e.g., neutropenia and mucositis), respectively.</p><p><strong>Conclusion: </strong>Considering the higher rate of adverse events in the DCF group, besides the significant improvement of OS and the acceptable adverse event profile of patients treated with the FLOT regimen, it can be proposed that this chemotherapy regimen is the most appropriate treatment option for elderly patients with resectable gastric cancer.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"79"},"PeriodicalIF":1.5,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the severity of alopecia areata associated with arterial stiffness?","authors":"Mohammad Taghi Najafi, Robabeh Abedini, Narges Ghandi, Shadab Seraji, Yasaman Sadeghi","doi":"10.4103/jrms.jrms_375_23","DOIUrl":"10.4103/jrms.jrms_375_23","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the severity of alopecia areata (AA) associations with metabolic syndrome, body composition evaluated by bioimpedance techniques, and arterial stiffness based on pulse-wave velocity analysis.</p><p><strong>Materials and methods: </strong>This cross-sectional study was conducted on patients referred to AA Clinic at Razi Hospital in 2021 and 2022. Patients with AA with the Severity of Alopecia Tool (SALT) score above 20% and receiving no systemic therapy were included. Patient demographic and clinical information, symptoms of metabolic syndrome, and bioimpedance factors were collected, and the relationship between disease severity, metabolic syndrome, and bioimpedance indicators was evaluated.</p><p><strong>Results: </strong>In this study, 59 patients were examined, with 26 (44.07%) being female and 33 (55.93%) being male. The mean age of the patients was 37.42 years (standard deviation [SD] =11.28). The severity of the disease was assessed using the SALT score, with the mean severity in terms of the percentage being 69.83% (SD = 28.57%). In the regression model, SALT score was independently related to the severity of vascular stiffness after adjusting for the effect of other variables (beta = 0.033, 95% CI = 0.009-0.057, <i>P</i> = 0.046). Moreover, SALT score was significantly related to metabolic syndrome after adjusting for the effect of other variables (OR = 1.035, 95% CI = 1.012-1.059, <i>P</i> = 0.002).</p><p><strong>Conclusion: </strong>This study found that AA severity is associated with a higher chance of having metabolic syndrome and arterial stiffness which may lead to cardiovascular diseases in patients with AA, and screening patients regarding cardiometabolic diseases is mandated.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"80"},"PeriodicalIF":1.5,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of diet low in advanced glycation end products on appetite, body composition, and brown adipose tissue markers in patients with coronary artery disease treated with angioplasty: A randomized controlled trial.","authors":"Fatemeh Taheri, Ali Vasheghani-Farahani, Elaheh Honarkar-Shafie, Hamidreza Poorhosseini, Mehdi Yaseri, Mohammad Javad Hosseinzadeh-Attar","doi":"10.4103/jrms.jrms_293_23","DOIUrl":"10.4103/jrms.jrms_293_23","url":null,"abstract":"<p><strong>Background: </strong>Recent changes in dietary habits have resulted in increased intake of advanced glycation end products (AGEs), which are known to have a predominant contribution to the pathogenesis and complications of coronary artery disease (CAD). AGEs are also thought to induce weight gain by affecting appetite, energy expenditure, and brown adipose tissue (BAT). Here, we investigated whether the restriction of dietary AGEs could affect appetite, body composition, anthropometric indices, and BAT-derived markers in CAD patients treated with angioplasty.</p><p><strong>Materials and methods: </strong>Forty-two stented CAD patients were randomly allocated into two groups that received either a low-AGEs or a control diet for 12 weeks. At baseline and postintervention, fasting blood samples were analyzed for total AGEs, nesfatin-1, and BAT-derived markers (fibroblast growth factor 21 and neuregulin 4). Subjective appetite ratings and body composition were evaluated using the Visual Analog Scale (VAS) and bioelectric impedance analysis. Anthropometric indices, including fat mass index (FMI), abdominal volume index (AVI), and body adiposity index (BAI), were calculated through the relevant formula.</p><p><strong>Results: </strong>Restricting dietary AGEs for 12 weeks could cause a significant reduction in weight, FMI, AVI, and BAI (<i>P</i> < 0.05) compared to the comparison group. In addition, VAS data analyses indicated a significant decrease in the sense of hunger and prospective food intake (<i>P</i> < 0.05) in the intervention group compared to the comparison group. No significant difference was seen in the measured biochemical markers between the two groups.</p><p><strong>Conclusion: </strong>This study indicated that the low-AGEs diet could decrease appetite, weight, and anthropometric indices in stented CAD patients.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"75"},"PeriodicalIF":1.6,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The denervation or activation of renal sympathetic nerve and renal blood flow.","authors":"Fatemeh Kharazmi, Hajaralsadat Hosseini-Dastgerdi, Ali-Asghar Pourshanazari, Mehdi Nematbakhsh","doi":"10.4103/jrms.jrms_216_23","DOIUrl":"10.4103/jrms.jrms_216_23","url":null,"abstract":"<p><p>The denervation or activation of the sympathetic nerve in the kidney can affect renal hemodynamics. The sympathetic nervous system regulates the physiological functions of the kidneys. Stimulation of sympathetic efferent nerves affects various parameters related to renal hemodynamics, including sodium excretion, renin secretion, and renal blood flow (RBF). Hence, renal sympathetic fibers may also play an essential role in regulating systemic vascular resistance and controlling blood pressure. In the absence of renal nerves, the hemodynamics response to stimuli is negligible or absent. The effect of renal sympathetic denervation on RBF is dependent on several factors such as interspecies differences, the basic level of nerve activity in the vessels or local density of adrenergic receptor in the vascular bed. The role of renal denervation has been investigated therapeutically in hypertension and related disorders. Hence, the dynamic impact of renal nerves on RBF enables using RBF dynamic criteria as a marker for renal denervation therapy.</p>","PeriodicalId":50062,"journal":{"name":"Journal of Research in Medical Sciences","volume":"28 ","pages":"76"},"PeriodicalIF":1.6,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}